JPMorgan initiated coverage of Eikon Therapeutics (EIKN) with an Overweight rating and $29 price target The company’s portfolio, led by Keytruda ex-developers, is well positioned with two advanced assets through in-licenses and a homegrown pipeline “built from its super resolution microscopy discovery engine,” the analyst tells investors in a research note.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EIKN:
- Eikon Therapeutics initiated with an Overweight at Morgan Stanley
- Spotify upgraded, First Solar downgraded: Wall Street’s top analyst calls
- Wedbush starts Eikon at Underperform on ‘significant clinical risk’
- Eikon Therapeutics initiated with an Underperform at Wedbush
- Opening Day: SpyGlass Pharma soars in debut after strongly priced IPO